Monogenic forms of mineralocorticoid hypertension: Insights into the pathogenesis of 'essential' hypertension?

Journal of Human Hypertension

Volumn 12, Issue 1, 1998, Pages 7-12

  Petrelli, M ^a   Stewart, P M ^a,b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

11 hydroxysteroid dehydrogenase; Cortisol; Hyperaldosteronism; Inheritance; Liddle's syndrome; Mineralocorticoid

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID;

ESSENTIAL HYPERTENSION; HYPERALDOSTERONISM; LIDDLE SYNDROME; PATHOGENESIS; REVIEW;

EID: 0031965226     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000512     Document Type: Review

References (73)

1. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion, and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966; 95: 1109-1119.
2. New MI, Peterson RE. A new form of congenital adrenal hyperplasia. J Cin Endocrinol Metab 1967; 27: 300-305.
3. Giebink GS et al. A kindred with familial glucocorticoid-suppressible hyperaldosteronism. J Clin Endocrinol Metab 1973; 36: 715-723.
4. Grim CE, Weinberger MH. Familial dexamethasone-suppressible normokalaemic hyperaldosteronism. Pediatrics 1980; 65: 597-604.
5. Ganguly A et al. Genetic and pathophysiologic studies of a new kindred with glucocorticoid-suppressible hyperaldosteronism manifest in three generations. J Clin Endocrinol Metab 1981; 53: 1041-1046.
6. Gill JR, Bartter FC. Overproduction of sodium-retaining steroids by the zona glomerulosa is adrenocorticotropin-dependent and mediates hypertension in dexamethasone-suppressible hyperaldosteronism. J Clin Endocrinol Metab 1981; 53: 331-337.
7. Bravo E et al. The changing clincal spectrum of primary aldosteronism. Am J Med 1983; 74: 641-651.
8. Fallo F et al. A new family with dexamethasone suppressible hyperaldosteronism: Aldosterone unresponsiveness to angiotensin II. Clin Endocrinol 1985; 22: 777-785.
9. Fallo F, Mantero F. Dexamethasone-suppressible hyperaldosteronism. In: Biglieri EG, Melby JC (eds). Endocrine hypertension. Raven Press: New York, 1990, pp 87-97.
10. Rich GM et al. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Annal Intern Med 1992; 116: 813-820.
11. Oberfield SE et al. Adrenal glomerulosa function in patients with dexamethasone-suppressible hyperaldosteronism. J Clin Endocrinol Metab 1981; 53: 158-1664.
12. Connell JMC et al. Glucocorticoid-suppressible hyperaldosteronism: Steroid and body electrolyte measurements and responses to angiotensin II and adrenocorticotropin. In: Mantero F, Biglieri EG, Funder JW (eds). The Adrenal Gland and Hypertension. Raven Press: New York, 1985, pp 405-420.
13. Ganguly A et al. Adrenal steroid response to ACTH in glucocorticoid-suppressible hyperaldosteronism. Hypertension 1984; 6: 563-566.
14. Rauh W et al. Mineralocorticoids, salt balance, and blood pressure after prolonged ACTH administration in juvenile hypertension. Klin Wochenschr 1978; 56: 161-168.
15. Pascoe L et al. Glucocorticoid-suppressible hyperaldosteronism and adrenal tumours in a single french pedigree. J Clin Invest 1995; 96: 2236-2246.
16. Woodland E et al. Hypertension corrected and aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressible hyperaldosteronism. Clin Exp Pharmacol Physiol 1985; 12: 245-248.
17. Gomez-Sanchez CE et al. Elevated urinary excretion of 18-oxocortisol in glucocorticoid-suppressible hyperaldosteronism. J Clin Endocrinol Metab 1984; 59: 1022-1024.
18. Ulick S et al. Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1990; 71: 1151-1157.
19. Davies JRE et al. Dexamethasone-suppressible hyperaldosteronism: Studies on overproduction of 18-hydroxycortisol in three affected family members. Clin Endocrinol 1988; 29: 297-308.
20. Lifton RP et al. Hereditary hypertension caused by chiameric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 1992; 2: 66-74.
21. Lifton RP et al. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable hyperaldosteronism and human hypertension. Nature 1992; 355: 262-265.
22. Chua SC et al. Cloning of cDNA encoding steroid 11-hydroxylase (P450 c11). Proc Natl Acad Sci USA 1987; 84: 7193-7197.
23. Mornet E, Dupont B, Vitek A, White PC. Characterization of two genes encoding human steroid 11β-hydroxylase (P-450 11β). J Biol Chem 1989; 264: 20961-20967.
24. Kawamoto T et al. Role of steroid 11β-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc Natl Acad Sci USA 1992; 89: 1458-1462.
25. Pascoe L et al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2, Proc Natl Acad Sci USA 1992; 89: 8327-8331.
26. Jamieson A et al. Rapid diagnosis of glucocorticoid-suppressible hyperaldosteronism in infants and adolescents. Arch Dis Child 1994; 71: 40-43.
27. Stowasser M et al. Clinical, biochemical and genetic approaches to the detection of familial hyperaldosteronism type I. J Hypertens 1995; 13: 1610-1613,
28. Jamieson A et al. Glucocorticoid-suppressible hyperaldosteronism: effects of cross-over site and parental origin of chimaeric gene. Clin Sci 1995; 88: 563-570.
29. Stockigt JR, Scoggins BA. Long-term evolution of glucocorticoid suppressible hyperaldosteronism. J Clin Endocrinol Metab 1987; 64: 22-26.
30. Liddle GW, Bledsoe T, Coppage WS. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Phys 1963; 76: 199-213.
31. Wang C et al. The effect of triamterene and sodium intake on renin, aldosterone and erythrocyte sodium transport in Liddle's syndrome. J Clin Endocrinol Metab 1981; 52: 1027-1032.
32. Nakada T et al. Liddle's syndrome, an uncommon form of hyporeninaemic hypoaldosteronism: functional and histopathological studies. J Urol 1987; 137: 636-640.
33. Botero-Valez M, Curtis JJ, Warnock DG. Brief report: Liddle's syndrome revisited - a disorder of sodium reabsorption in the distal tubule. N Eng J Med 1994; 330: 178-181.
34. Gardner JD, Lapey A, Simopoulos P, Bravo EL. Abnormal membrane sodium transport in Liddle's syndrome. J Clin Invest 1971; 50: 2253-2258.
35. Shimkets RA et al. Liddle's syndrome: heritable human hypertension caused by mutations in the β-subunit of the epithelial sodium channel. Cell 1994; 79: 407-414.
36. Hansson JH et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet 1995; 11: 76-82.
37. Snyder PM et al. Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial sodium channel. Cell 1995; 83: 969-978.
38. Ulick S et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49: 757-764.
39. Shackleton CHL, Stewart PM. The hypertension of apparent mineralocorticoid excess (AME) syndrome. In: Biglieri EG, Melby JE (eds). Endocrine Hypertension. 1990, Raven Press Ltd: New York, pp 155-173.
40. Shackleton CHL et al. Hypertension in a four-year-old child: gas chromatographic and mass spectrometric evidence for deficient hepatic metabolism of steroids. J Clin Endocrinol Metab 1980; 50: 786-792.
41. Shackleton CHL et al. Congenital 11β-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension. Corticosteroid metabolite profiles of four patients and their families. Clin Endocrinol 1985; 22: 701-712.
42. Monder C et al. The syndrome of apparent mineralocorticoid excess: its association with 11β-dehydrogenase and 5β-reductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab 1986; 63: 550-557.
43. Honour JW, Dillon MJ, Levin M, Shah V. Fatal, lowrenin hypertension associated with a disturbance of cortisol metabolism. Arch Dis Child 1983; 58: 1018-1020.
44. Stewart PM, Corrie JET, Shackleton CHL, Edwards CRW. Syndrome of apparent mineralocorticoid excess: A defect in the cortisol - cortisone shuttle. J Clin Invest 1988; 82: 340-349.
45. Dimartino-Nardi J et al. New findings in apparent mineralocorticoid excess. Clin Endocrinol 1988; 27: 49-62.
46. Stewart PM et al. Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase comes of age. Lancet 1987; i: 1208-1210.
47. Stewart PM et al. Mineralocorticoid activity of carbenoxolone: Contrasting effects of carbenoxolone and liquorice on 11β-hydroxysteroid dehydrogenase activity in man. Clin Sci 1990; 78: 49-54.
48. Souness GW, Morris DJ. The antinatriuretic and kaluretic effects of the glucocorticoids corticosterone and cortisol following pre-treatment with carbenoxolone sodium (a liquorice derivative) in the adrenalectomized rat. Endocrinology 1989; 124: 1588-1590.
49. Farese RV et al. Licorice-induced hypermineralocorticoidism. N Engl J Med 1991; 325: 1225-1227.
50. Arriza JL et al. Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science 1987; 237: 268-275.
51. Krozowski K, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA, 1983; 80: 6056-6060.
52. Edwards CRW et al. Localisation of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988; ii: 986-989.
53. Funder JW, Pearce PT, Smith R, Smith AI. Mineral-ocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242: 583-585.
54. Tannin GM et al. The human gene for 11β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 1991; 266: 16653-16658.
55. Brown RW, Chapman KE, Edwards CRW, Seckl JR. Human placental 11β-hydroxysteroid dehydrogenase: Evidence for and partial purification of a distinct NAD-dependent isoform. Endocrinology 1993; 132: 2614-2621.
56. +-dependent enzyme and differs from the cloned 'type 1' isoform. J Clin Endocrinol Metab 1994; 79: 480-484.
57. Albiston AL, Obeyesekero VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105: R11-R17.
58. Agarwal AK, Rogerson FM, Mune T, White PC. Gene structure and chromosomal localization of the human D11K gene encoding the kidney (type 2) isozyme of 11β-hydroxysteroid dehydrogenase. Genomics 1995; 29: 195-199.
59. Wilson RC et al. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1995; 80: 2263-2266.
60. Mune T et al. Human hyypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat Genet 1995; 10: 394-399.
61. Stewart PM et al. Human hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the type 2 11β-hydioxysteroid dehydrogenase gene. Lancet 1996; 347: 88-91.
62. White PC, Mune T, Agarwal AK. 11β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endo Rev 1997; 18: 135-156.
63. Gadallah MF, Abreo K, Work J. Liddle's syndrome, an unrecognised entity: a report of four cases including the first report in black individuals. Am J Kid Dis 1995; 25: 829-835.
64. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 1995; 60: 48-51.
65. Gordon RD. Heterogenous hypertension. Nat Genet 1995; 11: 6-9.
66. Walker BR et al. Deficient inactivation of cortisol by 11β-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol 1993; 39: 221-227.
67. Soro A et al. Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in patients with untreated essential hypertension. Hypertension 1995; 25: 67-70.
68. DeSimone G et al. Partial deficiency of adrenal 11-hydroxylase. A possible cause of primary hypertension. Hypertension 1985; 7: 204-210.
69. Tarazi RC et al. Haemodynamic characteristics of primary aldosteronism. N Engl J Med 1973; 289: 1330-1335.
70. Gomez-Sanchez EP, Gomez-Sanchez CE. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am J Physiol 1992; 263: E1125-E1130.
71. Walker BR, Connacher AA, Webb DJ, Edwards CRW. Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man. Clin Sci 1992; 83: 171-178.
72. Kernel L. Colocalization of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994; 7: 100-103.
73. Edwards CRW, Benediktsson R, Lindsay RS, Seckl JR. Dysfunction of placental glucocorticoid barrier: link between fetal environment and adult hypertension? Lancet 1993; 341: 355-357.